De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report
出版年份 2022 全文链接
标题
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report
作者
关键词
-
出版物
Nature Communications
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-03-17
DOI
10.1038/s41467-022-29104-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
- (2021) Goran Kokic et al. Nature Communications
- SARS-CoV-2 evolution during treatment of chronic infection
- (2021) Steven A. Kemp et al. NATURE
- Engineering SARS-CoV-2 using a reverse genetic system
- (2021) Xuping Xie et al. Nature Protocols
- SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms
- (2021) Sarah A. Clark et al. CELL
- Multiplex qPCR discriminates variants of concern to enhance global surveillance of SARS-CoV-2
- (2021) Chantal B. F. Vogels et al. PLOS BIOLOGY
- Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail
- (2021) Arnaud C. Drouin et al. Viruses-Basel
- In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2
- (2021) Agnieszka M. Szemiel et al. PLoS Pathogens
- A serological assay to detect SARS-CoV-2 seroconversion in humans
- (2020) Fatima Amanat et al. NATURE MEDICINE
- Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
- (2020) Wanchao Yin et al. SCIENCE
- First case of persistent pancytopenia associated with SARS-CoV-2 bone marrow infiltration in an immunocompromised patient
- (2020) N. Issa et al. ANNALS OF ONCOLOGY
- Longitudinal analyses reveal immunological misfiring in severe COVID-19
- (2020) Carolina Lucas et al. NATURE
- A single-cell atlas of the peripheral immune response in patients with severe COVID-19
- (2020) Aaron J. Wilk et al. NATURE MEDICINE
- Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
- (2020) Alina Baum et al. SCIENCE
- Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
- (2020) Johanna Hansen et al. SCIENCE
- Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection
- (2020) Jin Wei et al. CELL
- Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19
- (2020) Martin Martinot et al. CLINICAL INFECTIOUS DISEASES
- Sensitive recovery of complete SARS-CoV-2 genomes from clinical samples using Swift Biosciences' SARS-CoV-2 multiplex amplicon sequencing panel
- (2020) Amin Addetia et al. JOURNAL OF CLINICAL MICROBIOLOGY
- REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
- (2020) Alina Baum et al. SCIENCE
- Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer
- (2020) Victoria A. Avanzato et al. CELL
- Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
- (2020) Bina Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report
- (2020) Matthew S. Buckland et al. Nature Communications
- SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication
- (2020) Soren Alexandersen et al. Nature Communications
- Nextstrain: real-time tracking of pathogen evolution
- (2018) James Hadfield et al. BIOINFORMATICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now